ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
SpringWorks Therapeutics Inc

SpringWorks Therapeutics Inc (SWTX)

36.08
-0.05
(-0.14%)
終了 1月3日 6:00AM
36.08
0.00
(0.00%)
取引時間後: 8:56AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
36.08
買値
35.38
売値
37.40
出来高
611,365
35.99 日の範囲 37.8775
28.21 52 週間の範囲 53.92
時価総額
前日終値
36.13
始値
36.34
最終取引時間
財務取引量
US$ 22,559,238
VWAP
36.8998
平均取引量 (3 か月)
1,120,420
発行済株式数
74,386,403
配当利回り
-
PER
-8.26
1 株当たり利益 (EPS)
-4.37
歳入
5.45M
純利益
-325.1M

SpringWorks Therapeutics Inc について

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differenti... SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. 詳細を表示

セクター
Biological Pds,ex Diagnstics
業界
Biological Pds,ex Diagnstics
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
SpringWorks Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker SWTX. The last closing price for SpringWorks Therapeutics was US$36.13. Over the last year, SpringWorks Therapeutics shares have traded in a share price range of US$ 28.21 to US$ 53.92.

SpringWorks Therapeutics currently has 74,386,403 shares in issue. The market capitalisation of SpringWorks Therapeutics is US$2.69 billion. SpringWorks Therapeutics has a price to earnings ratio (PE ratio) of -8.26.

SWTX 最新ニュース

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors...

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib...

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN – – Patients achieved deep and durable...

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with...

SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.48-1.3129102844636.5637.399935.3960332136.45051846CS
4-5.77-13.787335722841.8542.9434.35595512237.921957CS
125.417.601043024830.6844.9228.21112042035.50771599CS
26-2.29-5.968204326338.3744.9228.2199480035.91273526CS
52-0.02-0.055401662049936.153.9228.21100080840.3642927CS
156-25.88-41.768883150461.9666.11513.686691333.75038604CS
260-2.41-6.2613665887238.4996.4813.662305138.6928302CS

SWTX - Frequently Asked Questions (FAQ)

What is the current SpringWorks Therapeutics share price?
The current share price of SpringWorks Therapeutics is US$ 36.08
How many SpringWorks Therapeutics shares are in issue?
SpringWorks Therapeutics has 74,386,403 shares in issue
What is the market cap of SpringWorks Therapeutics?
The market capitalisation of SpringWorks Therapeutics is USD 2.69B
What is the 1 year trading range for SpringWorks Therapeutics share price?
SpringWorks Therapeutics has traded in the range of US$ 28.21 to US$ 53.92 during the past year
What is the PE ratio of SpringWorks Therapeutics?
The price to earnings ratio of SpringWorks Therapeutics is -8.26
What is the cash to sales ratio of SpringWorks Therapeutics?
The cash to sales ratio of SpringWorks Therapeutics is 492.9
What is the reporting currency for SpringWorks Therapeutics?
SpringWorks Therapeutics reports financial results in USD
What is the latest annual turnover for SpringWorks Therapeutics?
The latest annual turnover of SpringWorks Therapeutics is USD 5.45M
What is the latest annual profit for SpringWorks Therapeutics?
The latest annual profit of SpringWorks Therapeutics is USD -325.1M
What is the registered address of SpringWorks Therapeutics?
The registered address for SpringWorks Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the SpringWorks Therapeutics website address?
The website address for SpringWorks Therapeutics is www.springworkstx.com
Which industry sector does SpringWorks Therapeutics operate in?
SpringWorks Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
ONCBeiGene Ltd
 184.21
(731.65%)
132.21k
RAINRain Enhancement Technologies Holdco Inc
 6.75
(457.85%)
211.35k
NITON2OFF Inc
US$ 1.07
(331.45%)
603.87M
CTCXCarmell Corporation
US$ 0.6991
(150.48%)
314.15M
TXMDTherapeuticsMD Inc
US$ 1.58
(83.72%)
7.41M
NMRANeumora Therapeutics Inc
US$ 1.965
(-81.46%)
44.29M
THCHTH International Limited
US$ 0.71
(-80.00%)
46.39k
MARXMars Acquisition Corporation
US$ 2.47
(-73.58%)
1.19M
SISIShineco Inc
US$ 2.07
(-54.30%)
1.73M
MARXUMars Acquisition Corporation
US$ 6.23
(-40.10%)
66.1k
NITON2OFF Inc
US$ 1.07
(331.45%)
603.55M
MBIOMustang Bio Inc
US$ 0.2093
(18.25%)
310.88M
CTCXCarmell Corporation
US$ 0.6991
(150.48%)
309.04M
CGBSCrown LNG Holdings Ltd
US$ 0.6749
(68.68%)
278.33M
SVMHSRIVARU Holding Ltd
US$ 0.0599
(42.28%)
275.21M

SWTX Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock